PubMed

Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog.

Edgerton DS, Johnson KM, Neal DW, Scott M, Hobbs CH, Zhang X, Duttaroy A, Cherrington AD.

Diabetes. 2009 Jan;58(1):243-9. Epub 2008 Oct 7.PMID: 18840785 [PubMed - indexed for MEDLINE]Related articlesFree article

Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.

D'Alessio DA, Denney AM, Hermiller LM, Prigeon RL, Martin JM, Tharp WG, Saylan ML, He Y, Dunning BE, Foley JE, Pratley RE.

J Clin Endocrinol Metab. 2009 Jan;94(1):81-8. Epub 2008 Oct 28.PMID: 18957505 [PubMed - indexed for MEDLINE]Related articles

Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.

Rosenstock J, Foley JE, Rendell M, Landin-Olsson M, Holst JJ, Deacon CF, Rochotte E, Baron MA.

Diabetes Care. 2008 Jan;31(1):30-5. Epub 2007 Oct 18.PMID: 17947341 [PubMed - indexed for MEDLINE]Related articlesFree article

Intraportal GLP-1 infusion increases nonhepatic glucose utilization without changing pancreatic hormone levels.

Johnson KM, Edgerton DS, Rodewald T, Scott M, Farmer B, Neal D, Cherrington AD.

Am J Physiol Endocrinol Metab. 2007 Oct;293(4):E1085-91. Epub 2007 Aug 7.PMID: 17684104 [PubMed - indexed for MEDLINE]Related articlesFree article

DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell-specific overexpression of human islet amyloid polypeptide.

Ahrén B, Winzell MS, Wierup N, Sundler F, Burkey B, Hughes TE.

Regul Pept. 2007 Oct 4;143(1-3):97-103. Epub 2007 Apr 11.PMID: 17482289 [PubMed - indexed for MEDLINE]Related articles

Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs.

Deacon CF, Wamberg S, Bie P, Hughes TE, Holst JJ.

J Endocrinol. 2002 Feb;172(2):355-62.PMID: 11834453 [PubMed - indexed for MEDLINE]Related articlesFree article

Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats.

Burkey BF, Li X, Bolognese L, Balkan B, Mone M, Russell M, Hughes TE, Wang PR.

J Pharmacol Exp Ther. 2005 Nov;315(2):688-95. Epub 2005 Jul 18.PMID: 16027230 [PubMed - indexed for MEDLINE]Related articlesFree article

The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion.

El-Ouaghlidi A, Rehring E, Holst JJ, Schweizer A, Foley J, Holmes D, Nauck MA.

J Clin Endocrinol Metab. 2007 Nov;92(11):4165-71. Epub 2007 Aug 14.PMID: 17698900 [PubMed - indexed for MEDLINE]Related articlesFree article

The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with type 2 diabetes.

Zander M, Madsbad S, Deacon CF, Holst JJ.

Diabetologia. 2006 Feb;49(2):369-74. Epub 2005 Dec 30.PMID: 16385384 [PubMed - indexed for MEDLINE]Related articles

Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats.

Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li X.

Diabetologia. 1999 Nov;42(11):1324-31.PMID: 10550416 [PubMed - indexed for MEDLINE]Related articles

Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients.

Boschmann M, Engeli S, Dobberstein K, Budziarek P, Strauss A, Boehnke J, Sweep FC, Luft FC, He Y, Foley JE, Jordan J.

J Clin Endocrinol Metab. 2009 Mar;94(3):846-52. Epub 2008 Dec 16.PMID: 19088168 [PubMed - indexed for MEDLINE]Related articles

The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study.

Vella A, Bock G, Giesler PD, Burton DB, Serra DB, Saylan ML, Deacon CF, Foley JE, Rizza RA, Camilleri M.

Clin Endocrinol (Oxf). 2008 Nov;69(5):737-44. Epub 2008 Mar 10.PMID: 18331607 [PubMed - indexed for MEDLINE]Related articles

The role of vildagliptin in the management of type 2 diabetes mellitus.

Kleppinger EL, Helms K.

Ann Pharmacother. 2007 May;41(5):824-32. Epub 2007 Apr 24. Review.PMID: 17456545 [PubMed - indexed for MEDLINE]Related articles

The islet enhancer vildagliptin: mechanisms of improved glucose metabolism.

Ahrén B, Foley JE.

Int J Clin Pract Suppl. 2008 Mar;(159):8-14. Review.PMID: 18269436 [PubMed - indexed for MEDLINE]Related articles

Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes.

Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, Deacon CF, Holst JJ, Foley JE.

J Clin Endocrinol Metab. 2005 Aug;90(8):4888-94. Epub 2005 May 10.PMID: 15886245 [PubMed - indexed for MEDLINE]Related articlesFree article

Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes.

Azuma K, Rádiková Z, Mancino J, Toledo FG, Thomas E, Kangani C, Dalla Man C, Cobelli C, Holst JJ, Deacon CF, He Y, Ligueros-Saylan M, Serra D, Foley JE, Kelley DE.

J Clin Endocrinol Metab. 2008 Feb;93(2):459-64. Epub 2007 Nov 27.PMID: 18042650 [PubMed - indexed for MEDLINE]Related articlesFree article

Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice.

Flock G, Baggio LL, Longuet C, Drucker DJ.

Diabetes. 2007 Dec;56(12):3006-13. Epub 2007 Aug 23.PMID: 17717280 [PubMed - indexed for MEDLINE]Related articlesFree article

The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.

Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y, He YL, Darland C, Holst JJ, Deacon CF, Cusi K, Mari A, Foley JE, DeFronzo RA.

J Clin Endocrinol Metab. 2007 Apr;92(4):1249-55. Epub 2007 Jan 23.PMID: 17244786 [PubMed - indexed for MEDLINE]Related articlesFree article

Intraportally delivered GLP-1, in the presence of hyperglycemia induced via peripheral glucose infusion, does not change whole body glucose utilization.

Johnson KM, Edgerton DS, Rodewald T, Scott M, Farmer B, Neal D, Cherrington AD.

Am J Physiol Endocrinol Metab. 2008 Feb;294(2):E380-4. Epub 2007 Dec 4.PMID: 18056788 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs.

Nishizawa M, Moore MC, Shiota M, Gustavson SM, Snead WL, Neal DW, Cherrington AD.

Am J Physiol Endocrinol Metab. 2003 May;284(5):E1027-36. Epub 2003 Feb 4.PMID: 12569088 [PubMed - indexed for MEDLINE]Related articlesFree article